Kroesen B J, Bakker A, van Lier R A, The H T, de Leij L
Department of Clinical Immunology, University Hospital Groningen, The Netherlands.
Cancer Res. 1995 Oct 1;55(19):4409-15.
Induction of T-cell activation requires multiple signals provided by cell surface receptor interactions and/or cytokines. T-cell stimulation via the T-cell receptor/CD3 complex provides an important initial activation event which, when combined with the proper costimulatory signals, results in an activated effector T cell. In this report, we have investigated the effectiveness of epithelial glycoprotein-2- (EGP-2) positive tumor target cells to induce specific T-cell stimulation via CD3, CD5, and CD28 using various combinations of bispecific monoclonal antibodies (BsMab) directed against CD3, CD5, or CD28 on the one hand and the pancarcinoma-associated antigen EGP-2 on the other. Induction of T-cell activation was investigated by assessment of CD69 expression, induction of proliferation, and acquirement of cytolytic potential. EGP-2-specific induction of T-cell activation was observed using combinations of BsMab which simultaneous ligated CD3/CD5, CD3/CD28, or CD3/CD5/CD28 with EGP-2. Activation with CD3-, CD5-, or CD28-based BsMab alone did not result in significant induction of T-cell activation in the presence or absence of EGP-2-positive target cells. Simultaneous ligation via CD5/CD28 resulted in partial T-cell activation, including CD69 up-regulation and increased cytolytic activity. Stimulation via CD3 and CD5 or CD28 could be further increased by the addition of exogenously added recombinant Interleukin 2. In contrast, T-cell activation by simultaneous ligation of CD3/CD5/CD28 could not be further augmented by addition of exogenous interleukin 2, indicating that T-cell activation via the combination of CD3, CD5, and CD28 results in complete T-cell activation. Our results show that rapid and target cell-specific induction of T cells is possible using combinations of BsMab directed against different costimulatory molecules. Simultaneous costimulation via CD3/CD5/CD28 results in the most complete activation of T cells.
T细胞活化的诱导需要细胞表面受体相互作用和/或细胞因子提供的多种信号。通过T细胞受体/CD3复合物刺激T细胞提供了一个重要的初始活化事件,当与适当的共刺激信号结合时,会产生活化的效应T细胞。在本报告中,我们研究了上皮糖蛋白-2(EGP-2)阳性肿瘤靶细胞通过使用一方面针对CD3、CD5或CD28,另一方面针对泛癌相关抗原EGP-2的双特异性单克隆抗体(BsMab)的各种组合,经由CD3、CD5和CD28诱导特异性T细胞刺激的有效性。通过评估CD69表达、增殖诱导和细胞溶解潜能的获得来研究T细胞活化的诱导。使用同时将CD3/CD5、CD3/CD28或CD3/CD5/CD28与EGP-2连接的BsMab组合观察到了EGP-2特异性的T细胞活化诱导。单独使用基于CD3、CD5或CD28的BsMab活化,无论是否存在EGP-2阳性靶细胞,均未导致T细胞活化的显著诱导。通过CD5/CD28同时连接导致部分T细胞活化,包括CD69上调和细胞溶解活性增加。通过添加外源性重组白细胞介素2可进一步增强经由CD3和CD5或CD28的刺激。相反,添加外源性白细胞介素2不能进一步增强通过同时连接CD3/CD5/CD28引起的T细胞活化,这表明通过CD3、CD5和CD28的组合进行T细胞活化会导致T细胞的完全活化。我们的结果表明,使用针对不同共刺激分子的BsMab组合可以实现T细胞的快速和靶细胞特异性诱导。通过CD3/CD5/CD28同时进行共刺激会导致T细胞的最完全活化。